Literature DB >> 1535743

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.

H R McClelland1, A J Quinn.   

Abstract

Six patients with large uterine fibroids were given a single subcutaneous implant of an LHRH analogue (goserelin 3.5 mg) prior to elective hysterectomy. Overall fibroid volume decreased by 30-47% within six weeks of implantation. All patients reported improvement in their symptoms of pressure and pain, and were rendered amenorrhoeic prior to surgery.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1535743      PMCID： PMC2448785     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN： 0041-6193


  12 in total

1.  Rationale in use of LHRH analogues in endometriosis.

Authors:  R W Shaw
Journal:  Horm Res       Date:  1989

2.  Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.

Authors:  D L Healy; S R Lawson; M Abbott; D T Baird; H M Fraser
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

3.  Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.

Authors:  W H Matta; I Stabile; R W Shaw; S Campbell
Journal:  Fertil Steril       Date:  1988-06       Impact factor: 7.329

4.  Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium.

Authors:  T Tamaya; J Fujimoto; H Okada
Journal:  Acta Obstet Gynecol Scand       Date:  1985       Impact factor: 3.636

5.  Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients.

Authors:  J R Zorn; J Mathieson; F Risquez; A M Comaru-Schally; A V Schally
Journal:  Fertil Steril       Date:  1990-03       Impact factor: 7.329

6.  Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri.

Authors:  G B Candiani; P Vercellini; L Fedele; L Arcaini; S Bianchi; M Candiani
Journal:  Acta Obstet Gynecol Scand       Date:  1990       Impact factor: 3.636

7.  Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.

Authors:  W H Matta; R W Shaw; M Nye
Journal:  Br J Obstet Gynaecol       Date:  1989-02

8.  Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.

Authors:  C P West; M A Lumsden; S Lawson; J Williamson; D T Baird
Journal:  Fertil Steril       Date:  1987-07       Impact factor: 7.329

9.  Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.

Authors:  H A van Leusden; A A Dogterom
Journal:  Gynecol Endocrinol       Date:  1988-03       Impact factor: 2.260

10.  The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.

Authors:  M R Williams; K J Walker; A Turkes; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640
View more
  1 in total

Review 1.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.